Rubric Capital Management (New York)’s Edesa Biotech EDSA Stock Holding History

Rubric Capital Management (New York)’s Portfolio EDSA Stock Details EDSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.44M	Sell	669,500 -18,000	-3%	-$162K	0.05%	80
2026 Q1	$3.6M	Hold	687,500	–	–	0.04%	80
2025 Q4	$976K	Hold	687,500	–	–	0.01%	76
2025 Q3	$1.7M	Hold	687,500	–	–	0.02%	70
2025 Q2	$1.4M	Hold	687,500	–	–	0.02%	63
2025 Q1	$1.68M	Buy	+687,500	New	+$1.48M	0.03%	62

Other funds holding EDSA

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Rubric Capital Management (New York)'s EDSA Position: Q2 2026 in Review

Rubric Capital Management (New York) reduced its Edesa Biotech (EDSA) stake by 2.6% in Q2 2026, selling an estimated $162K and leaving 669,500 shares worth $5.44M. The position accounts for 0.05% of the portfolio, ranked #80.

Rubric Capital Management (New York) first reported a position in EDSA in Q1 2025 and has held it in 6 quarters since. 33 funds tracked by Wall St. Rank hold EDSA as of Q2 2026.

Rubric Capital Management (New York) held 669,500 shares of Edesa Biotech worth $5.44M as of Q2 2026.
Rubric Capital Management (New York) sold 18,000 Edesa Biotech shares in Q2 2026, an estimated $162K.
Edesa Biotech made up 0.05% of Rubric Capital Management (New York)'s portfolio in Q2 2026, its #80 holding.
Rubric Capital Management (New York) first reported a position in Edesa Biotech in Q1 2025 and has held it in 6 quarters since.
33 funds tracked by Wall St. Rank held Edesa Biotech as of Q2 2026.

Based on Rubric Capital Management (New York)'s 13F filing for Q2 2026, filed 14 Aug 2026.